HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE COVER ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a letter to the editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murr, M. M. Articles by van Heerden, J. A. Search for Related Content PubMed PubMed Citation Articles by Murr, M. M. Articles by van Heerden, J. A.

CA: A Cancer Journal for Clinicians, Vol 44, Issue 5 304-318, Copyright © 1994 by American Cancer Society

ARTICLES

Pancreatic cancer

M. M. Murr, M. G. Sarr, A. J. Oishi and J. A. van Heerden
Department of Surgery, Mayo Clinic, Rochester, Minnesota.

Pancreatic cancer is a devastating disease for the patient and presents challenging diagnostic and management problems for the physician. A range of serologic and radiologic studies are available for evaluation and staging of this disease. However, invasive studies, including laparotomy, are often necessary to establish the diagnosis and resectability. Despite advances in diagnostic technology that have shortened the interval between onset of symptoms and definitive treatment, no appreciable impact on survival has been demonstrated conclusively. Operative resection offers the only hope for cure, but fewer than 15 percent of patients have resectable disease at the time of diagnosis. Palliative therapy, whether operative or nonoperative, can be performed with low morbidity and provides significant relief of symptoms. Combined-modality treatment with chemotherapy and radiation therapy prolongs survival following curative resection.

This article has been cited by other articles:

				M. Bloomston, J. X. Zhou, A. S. Rosemurgy, W. Frankel, C. A. Muro-Cacho, and T. J. Yeatman Fibrinogen {gamma} Overexpression in Pancreatic Cancer Identified by Large-scale Proteomic Analysis of Serum Samples. Cancer Res., March 1, 2006; 66(5): 2592 - 2599. [Abstract] [Full Text] [PDF]

				G. Y. Yang, T. D. Wagner, M. Fuss, and C. R. Thomas Jr. Multimodality Approaches for Pancreatic Cancer CA Cancer J Clin, November 1, 2005; 55(6): 352 - 367. [Abstract] [Full Text] [PDF]

				T. Plath, M. Peters, K. Detjen, M. Welzel, Z. von Marschall, C. Radke, B. Wiedenmann, and S. Rosewicz Overexpression of pRB in Human Pancreatic Carcinoma Cells: Function in Chemotherapy-Induced Apoptosis J Natl Cancer Inst, January 16, 2002; 94(2): 129 - 142. [Abstract] [Full Text] [PDF]

				H. Ouyang, L.-j. Mou, C. Luk, N. Liu, J. Karaskova, J. Squire, and M.-S. Tsao Immortal Human Pancreatic Duct Epithelial Cell Lines with Near Normal Genotype and Phenotype Am. J. Pathol., November 1, 2000; 157(5): 1623 - 1631. [Abstract] [Full Text] [PDF]

				S. J. Miknyoczki, H. Chang, A. Klein-Szanto, C. A. Dionne, and B. A. Ruggeri The Trk Tyrosine Kinase Inhibitor CEP-701 (KT-5555) Exhibits Significant Antitumor Efficacy in Preclinical Xenograft Modelsof Human Pancreatic Ductal Adenocarcinoma Clin. Cancer Res., August 1, 1999; 5(8): 2205 - 2212. [Abstract] [Full Text] [PDF]

				N. Liu, T. Furukawa, M. Kobari, and M.-S. Tsao Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Human Pancreas and Pancreatic Carcinoma Am. J. Pathol., July 1, 1998; 153(1): 263 - 269. [Abstract] [Full Text] [PDF]